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Objectives: Protein induced by vitamin K absence or antagonist II (PIVKA-II), an abnormal form of prothrom-
bin, has been used as an aid in the diagnosis of hepatocellular cancer (HCC) as a tumor marker. We developed a
fully automated quantitative immunoassay for PIVKA-II on the ARCHITECT® i systems. The aim of this study was
to evaluate the analytical performance of this assay.
Design and Method: Assay imprecision, sensitivity, dilution linearity, high dose hook effect, sample type
equivalency, assay interferences of potential interfering materials and correlation with Picolumi PIVKA-II
(Eidia, Tokyo, Japan) were evaluated.
Results: The percentage coefﬁcient of variation (%CV) of total imprecision ranged from 2.8% to 5.4% with 10
levels of samples. The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ)were less than
0.63mAU/mL, 1.62mAU/mL, and 8.25mAU/mL, respectively. Linearity up to 30,000mAU/mL, no high dose hook
effect, no difference among sample types and no interference of commondrugs and endogenous substanceswere
observed. Correlation study with the Picolumi PIVKA-II gave a correlation coefﬁcient of 0.93 and a regression
slope of 1.07.
Conclusions: The results demonstrate that the fully automated prototype ARCHITECT PIVKA-II assay is an ac-
curate, highly sensitive and precise assay for the measurement of PIVKA-II levels in human sera and plasmas.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Liver cancer is the ﬁfthmost common cancer inmen and the seventh
in women but is the third leading cause of cancer death, because of its
high fatality rate (mortality is 93% of incidence) [1,2]. About 85% of
the burden is in developing counties with more than 50% in China
alone. The regionswith high incidence of liver cancer areWest and Cen-
tral Africa, and East and Southeast Asia. In contrast, incidence rates are
generally low in developed countries except Japan and Southern
Europe [1,2]. Hepatocellular carcinoma (HCC) is the major histologic
type among primary liver cancers occurring worldwide, accounting for
70% to 85% of total burden [3].absence or antagonist II; HCC,
tection; LoQ, limit of quantita-
atitis B virus; HCV, hepatitis C
-fetoprotein; AFP-L3, AFP frac-
mma-carboxyglutamic acid.
nt, Abbott Japan Co., Ltd., 278
ty of Clinical Chemists. PublishedChronic infection by either hepatitis B virus (HBV) or hepatitis C
virus (HCV) is a major risk factor for HCC. Approximately 80% of HCC
is estimated to be attributable to HBV or HCV worldwide [4]. Carcino-
genic risk of HBV carriers is 223-fold that of non-carriers [5]. Infection
by HCV is the most common predisposing factor in some developed
countries, including Japan [6].
Recently in some historical high risk regions, liver cancer rates de-
creased, possibly due to a reduction in HBV infection by improvement
of hygiene and sanitation conditions. In contrast, incident rates are in-
creasing in some developed areas, including the United State and Cen-
tral Europe, possibility due to the obesity epidemic and the rise in HCV
infection through continued transmission by injection drug users [7].
During the past three decades from 1980 to 2010, the overall age-
adjusted incidence rate of liver cancer in the United State has tripled
from 2.63 to 8.07 per 100,000 persons [8].
One of the reasons for the high fatality rate of HCC is the difﬁculty of
detection for HCC in early stage since it is an asymptomatic disease,
therefore many patients are not treated in the early stages. Early detec-
tion of HCC by surveillance in high risk groups is an appropriate way to
improve the survival rate in patients with HCC [9–14].by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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also known as des-gamma-carboxy prothrombin (DCP), is an abnormal
form of the coagulation protein, prothrombin. PIVKA-II is a functionally
defective prothrombin resulting from decline of the carboxylation of 10
glutamic acid residues at the N-terminus [15].
The level of PIVKA-II is elevated in patients with HCC. PIVKA-II level
is not correlated with the levels of alpha-fetoprotein (AFP) or AFP frac-
tion with afﬁnity to the Lens culinaris agglutinin (AFP-L3), which are
other representative biomarkers for HCC. Therefore PIVKA-II can be
used along with AFP or AFP-L3 as a complementary biomarker for
HCC. Thus, the combination of two markers enhances the sensitivity of
diagnosis of HCC, but minimizes the decrease in speciﬁcity [15–18].
The Japan Society of Hepatology recommends measurement of two or
more tumor markers for the diagnosis of small HCC [19].
Many studies showed serumPIVKA-II levels are related to tumor size,
vascular invasion, intrahepatic metastasis and frequency of recurrence
after treatment, so PIVKA-II also can be used as a prognostic predictor
in patients with HCC [20–24]. PIVKA-II may assume a crucial role to de-
cide the most effective therapy according to tumor characterization.
PIVKA-II has been used as an aid for diagnosis of HCC andmonitoring
of high risk patients (HCV infections, hepatitis/cirrhosis, HBV infections)
for development of HCC for more than 20 years in Japan [19].
We report here our development and evaluation of the analytical
performance of a fully automated immunoassay for PIVKA-II on the
ARCHITECT i systems (Abbott Japan, Tokyo, Japan).2. Materials and methods
2.1. Assay principle
The ARCHITECT PIVKA-II assay is a two-step immunoassay, using
chemiluminescent paramagnetic microparticle technology for quantita-
tive determination of PIVKA-II. The analyte, PIVKA-II, is captured bypara-
magnetic microparticles coated with a recombinant murine monoclonal
anti-PIVKA-II antibody 3C10 (Abbott Laboratories, IL, USA), which recog-
nizes an epitope in PIVKA-II within the gamma-carboxyglutamic acid
(GLA) domain (amino acid 13–27) at the N-terminus. The analyte-
microparticle complex is detected with an acridinium labeled murine
anti-prothrombin monoclonal antibody MCA 1–8 (Abbott Laboratories)
conjugate, which recognizes an epitope at the N-terminus in prothrom-
bin (Fig. 1).Fig. 1. Assay principal of the prototype Architect PIVKA-II assay. Capture antibody
recognize an epitope in the gamma-carboxyglutamic acid (GLA) domain (amino acid
(aa) 13–27), tracer antibody recognize an epitope in the prothrombin part.In the ﬁrst step, 30 μl of sample, 50 μl of assay buffer and 50 μl of anti-
PIVKA-II antibody coated microparticles are combined and incubated for
18min. After washing, 50 μl of acridinium labeled anti-prothrombin anti-
body conjugate is added and incubated for 4min. Following an additional
wash step, pre-trigger and trigger solutions are added to the reactionmix-
ture. The resulting chemiluminescent reaction is measured as relative
light units (RLUs). The RLUs detected by the ARCHITCT optical system is
related to the amount of PIVKA-II Ag in the sample. The assay is fully au-
tomated and an assay result can be obtained within 30 min after initial
sample aspiration. The measuring range of this assay was designed from
10 to 30,000 mAU/mL. Calibrators were prepared from PIVKA-II antigen
diluted in buffer solution containingbovine serumalbumin. The calibrator
levels are 0, 40, 100, 300, 5000 and 30,000 mAU/mL.
2.2. PIVKA-II antigen
PIVKA-II antigen was prepared from human prothrombin (Enzyme
Research, IN, USA) by a thermal decarboxylation method described by
Bajaj et al. [25]. PIVKA-II value of the antigen was determined by com-
parison to the Picolumi PIVKA-II Assay (Eidia, Tokyo, Japan).
2.3. Specimens
AFP positive specimens were obtained from ProMedDx, LLC (MA,
USA). Normal specimens from apparently healthy individuals were ob-
tained from ProMeDx, LLC, C-C Biotech (CA, USA) and Denka Seiken Co.,
Ltd. (Tokyo, Japan). All human specimens used for this study were col-
lected under institutional review board approved protocols.
2.4. Evaluation methods
Assay imprecision was evaluated according to the Clinical and Labo-
ratory Standards Institute (CLSI) guideline EP5-A3 [26]. Three levels of
buffer based PIVKA-II quality controls, four levels of serumbased panels
and three levels of plasma based panels were assayed in replicates of
three at two separate times per day for over 20 days using three lots
of reagents and four instruments including three different versions
(two i1000SR, one i2000SR and one i2000). A high plasma panel spiked
with PIVKA-II antigen at ~75,000 mAU/mL level was tested using the
1:10 autodilution protocol.
The limit of blank (LoB), limit of detection (LoD) and limit of quanti-
tation (LoQ) were determined according to the CLSI guideline EP17-A2
[27]. Four zero-concentration samples and eight low concentration
PIVKA-II samples (0.625, 1.25, 2.5, 5, 7.5, 9, 10, 15 mAU/mL) were
assayed in replicates of two during ﬁve different days using three re-
agent lots and ﬁve instruments (two i1000SR and three i2000). LoB
was set as the 95th percentile of the zero-concentration samples' values.
For LoD calculation, normality of the distribution of the lowest concen-
tration PIVKA-II sample which 95% replicate showed over LoB was
conﬁrmed using the Shapiro–Wilk test. After the conﬁrmation, LoD
was calculated using the equation: LoD = LoB + (Cβ ∗ SDS),
where Cβ = 1.645 / [1 − 1 / (4 ∗ f)], f = degrees of freedom of SDS,
SDS = standard deviation (SD) of the low concentration samples. LoQ
was set as the lowest concentration that showed a total error of 30%
(10% bias + 2 × 10% CV). LoB, LoD and LoQ were calculated from
merged data of all reagent lots on each instrument.
Reagent on-board stability studieswere performedwith three lots of
reagents using nine instruments. Three levels of buffer based PIVKA-II
quality controls, four levels of serum based panels and three levels of
plasma based panels were assayed in replicates of ﬁve at 20 test points
using reagents stored on-board the instrument during 30 days. A cali-
bration curve was established on the initial day and concentration of
each sample was determined using the stored calibration curve. Con-
centrations of the samples were evaluated for trending over time.
Dilution linearity was assessed according to the CLSI guideline EP06-
A [28] with two serum and one plasma specimens spikedwith PIVKA-II
Table 1
Total assay imprecision (%CV).
n = 120
Sample Instrument type i1000SR i1000SR i2000 i2000SR
Reagent lot number Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
Quality control-1 Mean (mAU/mL) 49.39 51.22 48.52 48.58 47.48 49.04 52.20 47.91 48.67 50.92 49.12 50.01
SD (mAU/mL) 2.07 1.62 1.83 2.08 1.68 2.06 1.73 1.70 1.83 1.63 1.50 1.47
CV 4.2% 3.2% 3.8% 4.3% 3.5% 4.2% 3.3% 3.5% 3.8% 3.2% 3.1% 2.9%
Quality control-2 Mean (mAU/mL) 484.59 512.08 470.81 478.84 484.71 475.68 490.87 471.31 477.95 488.49 487.93 496.88
SD (mAU/mL) 18.56 16.56 14.70 16.51 17.88 19.14 14.94 15.00 13.50 13.90 13.90 14.75
CV 3.8% 3.2% 3.1% 3.4% 3.7% 4.0% 3.0% 3.2% 2.8% 2.8% 2.8% 3.0%
Quality control-3 Mean (mAU/mL) 9779.61 9810.52 9392.19 9807.30 10,020.86 9505.93 9988.98 9284.40 9441.06 9877.19 9591.38 10,273.99
SD (mAU/mL) 388.25 358.94 312.28 368.43 413.75 385.90 486.79 374.25 271.04 530.93 441.68 398.87
CV 4.0% 3.7% 3.3% 3.8% 4.1% 4.1% 4.9% 4.0% 2.9% 5.4% 4.6% 3.9%
Serum panel-1 Mean (mAU/mL) 20.43 22.10 21.38 20.63 20.70 22.29 21.67 20.28 21.18 22.15 21.49 22.51
SD (mAU/mL) 0.92 0.97 0.90 1.00 1.06 1.03 1.04 0.88 0.85 1.01 0.91 0.98
CV 4.5% 4.4% 4.2% 4.8% 5.1% 4.6% 4.8% 4.3% 4.0% 4.6% 4.2% 4.4%
Serum panel-2 Mean (mAU/mL) 43.76 46.85 45.52 44.27 44.49 46.75 45.97 43.59 45.08 46.89 45.46 47.17
SD (mAU/mL) 1.66 1.53 1.38 1.79 1.85 1.68 1.33 1.75 1.61 1.85 1.87 1.66
CV 3.8% 3.3% 3.0% 4.0% 4.1% 3.6% 2.9% 4.0% 3.6% 3.9% 4.1% 3.5%
Serum panel-3 Mean (mAU/mL) 243.29 253.92 247.70 247.88 253.26 256.67 245.00 236.37 244.29 252.81 250.30 257.94
SD (mAU/mL) 7.98 7.75 8.91 9.45 8.04 8.26 6.95 7.67 7.30 7.56 8.13 8.38
CV 3.3% 3.1% 3.6% 3.8% 3.2% 3.2% 2.8% 3.2% 3.0% 3.0% 3.2% 3.2%
Serum panel-4 Mean (mAU/mL) 1934.50 1980.87 1909.98 1984.26 2048.24 1982.26 1922.53 1875.93 1911.39 1940.36 1974.14 2041.62
SD (mAU/mL) 57.55 64.10 55.73 71.37 69.50 59.05 61.05 59.63 61.92 66.57 69.08 68.79
CV 3.0% 3.2% 2.9% 3.6% 3.4% 3.0% 3.2% 3.2% 3.2% 3.4% 3.5% 3.4%
Plasma panel-1 Mean (mAU/mL) 26.33 28.51 28.49 26.52 26.60 29.63 27.42 25.84 27.92 27.95 26.92 29.08
SD (mAU/mL) 1.03 1.36 1.04 1.11 1.32 1.14 1.22 1.06 1.20 1.16 1.09 1.17
CV 3.9% 4.8% 3.6% 4.2% 5.0% 3.9% 4.4% 4.1% 4.3% 4.2% 4.0% 4.0%
Plasma panel-2 Mean (mAU/mL) 251.77 264.19 256.71 256.86 260.46 265.01 254.59 246.51 257.36 261.02 259.16 268.43
SD (mAU/mL) 7.17 8.16 10.30 7.62 9.27 8.22 8.27 7.25 7.93 8.07 9.43 8.02
CV 2.8% 3.1% 4.0% 3.0% 3.6% 3.1% 3.2% 2.9% 3.1% 3.1% 3.6% 3.0%
Plasma panel-3 Mean (mAU/mL) 77,267.12 78,785.77 74,362.72 78,800.74 81,700.78 76,808.19 75,779.80 71,850.25 72,301.50 75,424.25 76,125.15 78,788.15
SD (mAU/mL) 2302.29 2864.63 2426.01 2505.25 2351.07 2837.68 3225.02 2580.41 2507.28 3713.16 3626.03 2888.44
CV 3.0% 3.6% 3.3% 3.2% 2.9% 3.7% 4.3% 3.6% 3.5% 4.9% 4.8% 3.7%
CV: coefﬁcient of variation, SD: standard deviation.
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Table 2
LoB, LoD and LoQ using 5 instruments.
Instrument type/number LoB (mAU/mL) LoD (mAU/mL) LoQ (mAU/mL)
i2000-1 0.58 1.61 6.92
i2000-2 0.34 1.17 4.91
i2000-3 0.37 0.85 2.38
i1000SR-1 0.00 0.73 8.25
i1000SR-2 0.63 1.37 4.81
LoB: limit of blank, LoD: limit of detection, LoQ: limit of quantitation.
1333K. Fujita et al. / Clinical Biochemistry 48 (2015) 1330–1336antigen. The specimens were diluted from 100% to 0.01% with the
ARCHITECT PIVKA-II calibrator diluent across the measuring range. Re-
gression analyses of the observed diluted concentrations were com-
pared to expected values based on the corresponding concentration of
the undiluted specimen.
High dose hook effect was assessed by testing of high level PIVKA-II
samples beyond themeasuring range of the assay. The high level PIVKA-II
samples were prepared from pooled serum spiked with PIVKA-II antigen
to 60,000, 100,000, 200,000, 300,000, 400,000, and 600,000mAU/mL. All
samples were assayed in replicates of ﬁve using four instruments (three
i2000 and one i1000SR). Mean RLU of each sample was compared with
mean RLU of Calibrator-F, the highest level calibrator.
Sample type equivalency was evaluated with specimens drawn from
16 normal individuals using seven types of blood collection tubes (plain
serum tube (Terumo, Tokyo, Japan), SST tube (Becton, Dickinson and
Company (BD), NJ, USA), EDTA K2 tube (Terumo), EDTA Na2 tube
(Terumo), lithium heparin tube (Terumo), lithium heparin PST tube
(BD) and sodium heparin tube (Terumo)). 20 mAU/mL or 200 mAU/mL
of PIVKA-II antigen was spiked into each specimen and assayed in repli-
cates of three. The mean of the PIVKA-II value of each sample was com-
pared to mean value of the corresponding plain serum tube sample.Fig. 2. Evaluation of linearity and high dose hook effect. A) Relationship between expected PIV
observed concentrations in three samples (A-1 and A-2: serum samples, A-3: plasma sample). B
ments. Higher concentration gave higher RLU up to 600,000 mAU/mL.Assay interferences of potential interfering materials including en-
dogenous substances, nutritional supplements and therapeutic agents
were evaluated based on the CLSI guideline EP7-A2 [29]. Each material
was diluted with appropriate diluents and spiked into the ﬁve low
level serum samples and ﬁve high level serum samples prepared by
spiking with a high titer specimen. The diluent used for the preparation
of the spikedmaterialswas spiked into the low level and high level sam-
ples in the samemanner for use as controls. All sampleswere assayed in
replicates of twelve. Themean of the PIVKA-II value of each test sample
was compared to mean value of the corresponding control sample.
Correlation of the prototype ARCHITECT PIVKA-II with Picolumi
PIVKA-II across the measuring range was evaluated using 81 AFP posi-
tive sera and 151 normal sera. Statistical analyses for the correlation
were performed using Analyse-it version 2.30 (Analyse-it Software,
Ltd., Leeds, UK).
3. Results
The total imprecision determinedwith each sample type and instru-
ment type is shown in Table 1. The percentage coefﬁcient of variation
(%CV) was between 2.8 and 5.4 over the investigated concentration
range from 20.28 to 78,800.74 mAU/mL.
The LoB, LoD and LoQ ranged from0.00 to 0.63, from0.73 to 1.61 and
from 2.38 to 8.25 mAU/mL, respectively (Table 2).
The reagent on-board stability results showed no signiﬁcant change
of sample concentrations. The 95% conﬁdence interval of concentration
shift% from initial day to 30 days was 2.0% to 3.2%.
The linearity of this assay over the range of 3.85 to 39,991.70mAU/mL
using three samples is shown in Fig. 2-A. The Spearman's correlation co-
efﬁcient between expected values and observed values of each sample
was 1.00. The recovery of diluted samples ranged from 89% to 105%.KA-II concentrations calculated from dilution ratio and neat samples' concentration and
) Relationship between PIVKA-II concentrations and relative light units (RLUs) on 4 instru-
Table 3
Evaluation of sample type equivalence and potential interfering materials including endogenous substances, nutritional supplements and therapeutic agents.
a) Sample type equivalence
n = 48 (16 donors × 3 replicates) per condition
Specimen type Spiked PIVKA-II
concentration
% difference from plain tube
serum
Mean 95% conﬁdence
interval
SST serum 20 mAU/mL 2.1% 0.1% to 4.1%
200 mAU/mL 3.7% 1.6% to 5.8%
EDTA K2 plasma 20 mAU/mL 1.5% −0.6% to 3.6%
200 mAU/mL 1.1% −1.0% to 3.2%
EDTA Na2 plasma 20 mAU/mL 0.4% −1.3% to 2.1%
200 mAU/mL 0.9% −0.8% to 2.6%
Li Heparin plasma 20 mAU/mL −0.4% −2.1% to 1.3%
200 mAU/mL 1.8% 0.0% to 3.6%
Li Heparin (PST) plasma 20 mAU/mL 0.8% −1.0% to 2.6%
200 mAU/mL 2.6% 1.0% to 4.2%
Na Heparin plasma 20 mAU/mL 1.0% −0.7% to 2.7%
200 mAU/mL 3.1% 1.4% to 4.8%
b) Potential interfering materials
n = 60 (5 donors × 12 replicates) per condition
Potentially interferents Concentration PIVKA-II low level (20 mAU/mL) PIVKA-II high level (200 mAU/mL)
% Difference from control % Difference from control
Mean 95% conﬁdence interval Mean 95% conﬁdence interval
Bilirubin (conjugated) 20 mg/dL −2.0% −3.5% to−0.5% −1.6% −2.3% to−0.9%
Bilirubin (unconjugated) 20 mg/dL 1.2% −1.9% to 4.3% 0.8% −1.4% to 3.0%
Hemoglobin 500 mg/dL 7.2% 5.8% to 8.6% 5.2% 3.8% to 6.6%
Prothrombin 15 mg/dL 2.2% −1.2% to 5.6% 0.0% −1.5% to 1.5%
Total protein 12 g/dL −4.0% −6.9% to−1.1% −6.4% −7.5% to−5.3%
Triglycerides 3000 mg/dL 2.4% −0.2% to 5.0% 2.6% −0.5% to 5.7%
Acetaminophen 600 μg/mL 1.6% −0.1% to 3.3% −1.2% −2.2% to−0.2%
Acetylsalicylic acid 500 μg/mL 1.0% −0.5% to 2.5% −1.8% −6.5% to 2.9%
Ascorbate 500 μg/mL −0.2% −3.8% to 3.4% 0.2% −2.0% to 2.4%
Cisplatin 7.24 μg/mL −1.0% −4.9% to 2.9% −0.2% −1.8% to 1.4%
Fluorouracil 100 μg/mL −2.2% −6.3% to 1.9% −0.4% −3.4% to 2.6%
Galactose 2 mg/mL −2.0% −4.9% to 0.9% 0.6% −0.8% to 2.0%
Glucose 10 mg/mL −2.2% −4.6% to 0.2% −0.1% −1.6% to 1.4%
Ibuprofen 400 μg/mL −2.0% −6.9% to 2.9% −0.4% −3.0% to 2.2%
Interferon α 3000 IU/mL 1.8% −0.2% to 3.8% 0.6% −0.5% to 1.7%
Interferon β 3000 IU/mL −1.8% −4.6% to 1.0% 0.4% −1.3% to 2.1%
Interferon γ 3000 IU/mL 0.8% −1.2% to 2.8% 0.0% −0.9% to 0.9%
Vitamin B1 140 μg/mL −2.3% −5.1% to 0.5% −0.6% −2.7% to 1.5%
Vitamin B6 500 μg/mL −2.2% −4.9% to 0.5% −0.2% −1.8% to 1.4%
Vitamin B12 250 μg/mL −0.2% −3.9% to 3.5% −0.6% −2.0% to 0.8%
a) Evaluation of sample type.
b) Evaluation of potential interfering materials.
1334 K. Fujita et al. / Clinical Biochemistry 48 (2015) 1330–1336No high dose hook effect was observed in the testing conditions, up
to 600,000 mAU/mL (Fig. 2-B). Higher concentration samples gave
higher RLU and no samples showed lower RLU than Calibrator-F RLU
(30,000 mAU/mL, upper limit of the measuring range).
The value differences between plain serum and various types of
specimens are shown in Table 3-a. The mean percentage differences of
each specimen type ranged from−0.4% to 3.7%.
The effects of potential interfering materials are shown in Table 3-b.
The mean percentage differences between test samples and control
samples ranged from−6.4% to 7.2%.
The correlation between the Picolumi PIVKA-II and the prototype
ARCHITECT PIVKA-II is shown in Fig. 3. The regression slope calculated
using the Passing-Bablok regression method was 1.07. The Spearman's
correlation coefﬁcient was 0.93.
4. Discussion
In the present study, the analytical performance of ARCHITECT PIVKA-
II assay was evaluated. The assay demonstrated good precision and high
sensitivity. There is viability in LoQ (2.38–8.25 mAU/mL), but the highest
LoQwas less than 10mAU/mL against the reported cut-off of 40mAU/mL[30]. The good linearity over the measuring range, no hook effect up to
600,000mAU/mL and no interference of common therapeutic agents, nu-
tritional supplements and endogenous substances were conﬁrmed. We
demonstrated that the ARCHITECT PIVKA-II Assay can be used with vari-
ous types of serum and plasma samples. The correlation data showed the
prototype ARCHITECT PIVKA-II gives equivalent PIVKA-II values to those
of the Picolumi PIVKA-II, the regulatory approved PIVKA-II assay in Japan.
In Japan, PIVKA-II has been commonly employed as a HCC speciﬁc
tumormarker. The Japan Society of Hepatology recommended themea-
surement of tumor markers combined with ultrasonography at inter-
vals of 2–6 months for regular screening in high risk patients with
type C chronic liver disease, type B chronic liver disease and cirrhosis
[19]. Since PIVKA-II, AFP and AFP-L3 are complementary biomarkers,
measurement of two ormore tumormarkers is useful for a precise diag-
nosis of HCC [15–18]. The National Health Insurance in Japan covers
measurements of AFP, PIVKA-II and AFP-L3. In contrast, outside Japan
only ultrasonography and AFP are commonly used for monitoring of
the high risk patients and there are no guidelines regarding PIVKA-II
usage for diagnosis of HCC so far.
Although prompt determination of the PIVKA-II level is important
for an appropriate treatment decision, it has not been achieved so far
Fig. 3. Correlation between the Japan-approved PIVKA-II assay kit, Picolumi PIVKA-II, and
the Architect PIVKA-II assay.
1335K. Fujita et al. / Clinical Biochemistry 48 (2015) 1330–1336even in Japan. Because the instrument used for the most predominant
assay kit for PIVKA-II in Japan is not prevalent in clinics and hospitals.
Therefore most samples are shipped to and assayed in commercial clin-
ical laboratories which take several days to report the assay results after
the initial sample collection. Because the second major assay kit,
Lumipulse PIVKA-II, in Japan can't use plasma samples, collected blood
samples must be held for more than 30 min. to allow the serum to
clot, it is difﬁcult to obtain the assay result before medical treatment
for ambulatory in a routine medical care process within a day.
Although human prothrombin is digested to several subfragments
by serine proteases activated in the coagulation cascade [31], the assay
can detect PIVKA-II in both serum and plasma without the inﬂuence
of degradation of analyte and the interference by the subfragments be-
cause both antibodies used for the ARCHITECT PIVKA-II assay recognize
epitopes at the N-terminus in PIVKA-II.
Current assay kits for PIVKA-II on market have some weaknesses.
Picolumi kit needs manual dilution steps for sample preparation and
Lumipulse and μTAS Wako DCP can't be used for plasma samples. The
ARCHITECT PIVKA-II assay is a convenient fully automated assay
which has a good analytical performance with high throughput (200
tests/h) without the pretreatment of specimens. The ARCHITECT
PIVKA-II assay was designed to be used with various types of plasma
as well as serum samples. Since the incubation time for coagulation is
not required for plasma samples, the assay results can be obtained ear-
lier than serum samples after the sample collection. These features
allow to test and obtain the test result before medical treatment in a
day when ambulatory patients visit.
This assay provides a convenient automated method for measure-
ment of PIVKA-II in both serum and plasma in clinics, hospitals and clin-
ical laboratories. It can support the global use of PIVKA-II for
management of HCC and the early detection of HCC in high risk groups.Conﬂict of interest
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